Last reviewed · How we verify
Fludarabine (Flud)
Fludarabine is a purine analog that inhibits ribonucleotide reductase and DNA polymerase, leading to disruption of DNA synthesis and cell death in rapidly dividing cells.
Fludarabine is a purine analog that inhibits ribonucleotide reductase and DNA polymerase, leading to disruption of DNA synthesis and cell death in rapidly dividing cells. Used for Chronic lymphocytic leukemia (CLL), Follicular lymphoma, Small lymphocytic lymphoma (SLL).
At a glance
| Generic name | Fludarabine (Flud) |
|---|---|
| Sponsor | Technische Universität Dresden |
| Drug class | Purine analog antimetabolite |
| Target | Ribonucleotide reductase, DNA polymerase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Fludarabine is a fluorinated purine nucleoside analog that is phosphorylated intracellularly to its active form, fludarabine triphosphate. This active metabolite inhibits ribonucleotide reductase and DNA polymerase, preventing DNA synthesis and repair. It is particularly effective against lymphoid malignancies because lymphocytes have high levels of deoxycytidine kinase, the enzyme responsible for its activation.
Approved indications
- Chronic lymphocytic leukemia (CLL)
- Follicular lymphoma
- Small lymphocytic lymphoma (SLL)
Common side effects
- Myelosuppression (neutropenia, thrombocytopenia, anemia)
- Infection
- Nausea and vomiting
- Fever
- Fatigue
- Neurotoxicity
- Tumor lysis syndrome
Key clinical trials
- Evaluation of Treosulfan Versus Melphalan Conditioning Followed by PTCy in Patients With AML and MDS Undergoing Allogeneic Transplantation (PHASE2)
- Treatment of Acute Lymphoblastic Leukemia HIGH RISK BCR / ABL NEGATIVE IN ADULTS
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |